NY-WISE
11.5.2021 12:02:04 CEST | Business Wire | Press release
Wise today announces an integration to bring Wise Platform to Google Pay users. Starting today, Google Pay users in the U.S. on iOS and Android devices are able to send money to their friends and family abroad within the Google Pay app, with access to Wise’s fast, cheap, and transparent services. The initial launch will enable Google Pay users in the U.S. to send money to Google Pay users in India and Singapore, with global send money capabilities to people in Wise’s 80+ country network later this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005412/en/
Wise Platform allows banks, businesses and software companies to tap into the Wise network, giving them and their customers access to cheaper, faster international payments, all through an integrated customer experience. Through the Wise Platform APIs, Google Pay’s U.S. users can now send money to friends and family internationally through Wise - all within the convenient Google Pay app.
The Wise Platform was built to bring international payments into the 21st century, and is now used by banks and businesses in over 10 markets. Wise’s APIs replace the existing patchwork systems banks and other payment providers use to move money internationally. In doing so, Wise enables consumers and businesses around the world to move money internationally faster and cheaper than ever before.
The initial integration of Wise Platform will be for U.S. Google Pay users sending money to friends and family using Google Pay in India and Singapore. Providing people with a simple and seamless way to send money to friends and family is more important than ever - particularly in India which is currently experiencing a devastating second wave of the coronavirus pandemic. According to The World Bank, India is the world’s foremost remittance destination.1 In Singapore, international inbound remittances have consistently grown since 2013, showing an increased demand among consumers for international payment services, such as Wise.2
Now, Google Pay customers in the U.S. can send money to India and Singapore with Wise without having to leave the Google Pay platform. And, unlike most banks and payments companies, Wise uses the real exchange rate with no hidden fees or markups. On average, Wise is eight times cheaper than most banks to send money internationally, saving its customers over $1 billion a year.
"Providing people with a simple and seamless way to safely send money to friends and family is more important than ever - be it for everyday use or in times of need," said Harsh Sinha, Chief Technology Officer at Wise. “Wise’s mission is money without borders - instant, convenient, transparent, and eventually, free. Through this collaboration, and with the integration of the Wise Platform, Google Pay customers can now send money internationally cheaper, faster, and easier.”
"Cross-border payments are not just a lifeline for loved ones, they form the financial backbone for many economies," said Josh Woodward, director of product management, Google Pay. "For many people with families abroad, sending money home is something they do as frequently as every month. By teaming up with Wise, we are providing a way for Google Pay users to send money quickly, safely and reliably from the Google Pay app."
For new customers, Wise will make the first transfer free on transfers up to USD$500 until June 16. By the end of the year, U.S. Google Pay users will be able to send money to 80 countries through Wise.
For more information on Wise Platform and capabilities, visit wise.com/us/business/api .
About Wise
Wise is a global technology company, building the best way to move money around the world. With the Wise account people and businesses can hold 54 currencies, move money between countries and spend money abroad. Huge companies and banks use Wise technology too; an entirely new cross-border payments network that will one day power money without borders for everyone, everywhere. However you use the platform, Wise is on a mission to make your life easier and save you money.
Co-founded by Taavet Hinrikus and Kristo Käärmann, Wise launched in 2011 under its original name TransferWise. It is one of the world’s fastest growing tech companies having raised over $1 billion in primary and secondary transactions from world leading investors.
10 million people and businesses use Wise, which processes over £4.5 billion in cross-border transactions every month, saving customers over £1 billion a year.
1
The World Bank: The Remittance Market in India
2
Ken Research: Singapore International Remittance Market Outlook to 2023 - By Inbound & Outbound Remittance, By Banking and Non-Banking Channel, By Inflow & Outflow Remittance Corridors
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005412/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
